These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
212 related items for PubMed ID: 9001768
21. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967 [Abstract] [Full Text] [Related]
23. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Rajpal RK, Fong R, Comstock TL. Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301 [Abstract] [Full Text] [Related]
24. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Sheppard JD, Comstock TL, Cavet ME. Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315 [Abstract] [Full Text] [Related]
25. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, McDonald MB, Perry HD, Lane SS, Pflugfelder SC, Samudre SS. Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776 [Abstract] [Full Text] [Related]
26. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Holland EJ, Djalilian AR, Sanderson JP. Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719 [Abstract] [Full Text] [Related]
27. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. Rajpal RK, Roel L, Siou-Mermet R, Erb T. J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817 [Abstract] [Full Text] [Related]
28. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Oner V, Türkcü FM, Taş M, Alakuş MF, Işcan Y. Jpn J Ophthalmol; 2012 Jul; 56(4):312-8. PubMed ID: 22622345 [Abstract] [Full Text] [Related]
29. Loteprednol etabonate: clinical potential in the management of ocular inflammation. Noble S, Goa KL. BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605 [Abstract] [Full Text] [Related]
39. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation. Howes JF, Baru H, Vered M, Neumann R. J Ocul Pharmacol; 1994 Jul; 10(1):289-93. PubMed ID: 8207332 [Abstract] [Full Text] [Related]
40. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation. Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI. Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]